ArticleScientific reports2025
The presence of neutralizing antibodies against omicron subvariants among a vaccinated cohort at one year after the first dose of vaccination in Malaysia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hybrid immunity following SARS-CoV-2 infection and vaccination is associated with more sustained antibody levels, and lower reinfection risk.Scientific reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study assesses the neutralizing antibodies response to Omicron subvariants and examines factors associated with seropositivity in a vaccinated Malaysian cohort. It is a prospective cohort study, conducted between June 2021 and October 2022. Descriptive and binary logistic regression analyses were performed on 1,117 adults aged 18 and above. Among the subvariants, seropositivity rates were: BA.2 (81.9%), BA.1 (68.4%), and BA.4/5 (64.2%). Non-Malaysians had significantly higher odds of testing positive for BA.2 compared to Malaysians (OR: 8.009; 95% CI: 1.273-50.402). Recipients of AstraZeneca (OR: 3.955; 95% CI: 2.414-6.482) and CanSino (OR: 1.980; 95% CI: 1.047-3.743) vaccines had higher odds of BA.2 seropositivity compared to Pfizer recipients. For BA.4/5, individuals aged 60 and above had greater odds of seropositivity (OR: 1.751; 95% CI: 1.029-2.979) compared to those aged 18-39. Chinese ethnicity was associated with lower odds of seropositivity than Malay ethnicity across BA.1 (OR: 0.508; 95% CI: 0.350-0.736), BA.2 (OR: 0.570; 95% CI: 0.377-0.861), and BA.4/5 (OR: 0.671; 95% CI: 0.467-0.963). This study highlights that completing primary vaccination and booster doses remains critical to reducing severe COVID-19 outcomes, underscoring the need for ongoing surveillance and targeted strategies for vulnerable demographic and socio-environmental groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.